Evidence map›Paper›PMID 34564838›Full record

ArticleCJEM2022

Barriers and attitudes reported by Canadian emergency physicians regarding the initiation of buprenorphine/naloxone in the emergency department for patients with opioid use disorder.

Tyson Savage, Marshall Ross

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in CJEM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Tyson SavageDepartment of Emergency Medicine, University of Calgary, 2nd Floor Foothills Medical Centre, 1403 29th Street, NW, Calgary AB, T2N 2T9, Canada. tyson.savage@ucalgary.ca.
Marshall RossDepartment of Emergency Medicine, University of Calgary, 2nd Floor Foothills Medical Centre, 1403 29th Street, NW, Calgary AB, T2N 2T9, Canada.

Funding

University of Calgary Grant Innes Resident Research Award
6 · The paper itself

Abstract

objectivesThe primary objective of this study is to identify emergency physician reported barriers to initiating patients on buprenorphine/naloxone in the emergency department (ED) for treatment of opioid use disorder. Secondary objectives include (1) physician reported attitudes about initiating buprenorphine/naloxone in the ED, and (2) comparison of barriers reported based on urban versus rural practice setting.

methodsAn online survey was distributed to a convenience sample of attending emergency physicians and resident physicians using the Canadian Association of Emergency Physicians (CAEP) research survey email distribution network.

resultsThe survey was sent to 1299 email accounts registered with the CAEP research survey network. We received 121 responses, which is a response rate of 9.3%. The completion rate was 118/121 (97.5%). Most respondents 113/118 (95.7%) reported at least one barrier that prevents them from initiating buprenorphine/naloxone in the ED. The top three reported barriers were (1) lack of allied health care staff who were trained to assist in starting patients on buprenorphine/naloxone in the ED and to help arrange follow-up, (2) time constraints related to patient education on the appropriate and safe use of buprenorphine/naloxone, and (3) access to follow-up resources. The majority of respondents agreed buprenorphine/naloxone was an evidence-based treatment for opioid use disorder and that it is important to make changes in their ED to better facilitate this practice. There was no statistically significant difference in the number of physicians reporting each barrier based on urban versus rural practice setting.

conclusionsIn this convenience sample of physicians working in urban and rural Canadian emergency departments, most physicians perceive barriers that inhibit their ability to initiate buprenorphine/naloxone for patients with opioid use disorder, but overall there is support for making changes to better facilitate this practice.

Indexed as

Opioid-Related DisordersPhysiciansAttitude of Health PersonnelBuprenorphine, Naloxone Drug CombinationCanadaEmergency Service, HospitalHumansNarcotic AntagonistsBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsAddictionsBuprenorphineOpioiud use disorder

Identifiers

PMID34564838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.